{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:50:28Z","timestamp":1787161828267,"version":"build-2736575974"},"reference-count":81,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004331","name":"Janssen Pharmaceutical Companies of Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.euo.2025.10.002","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T21:05:44Z","timestamp":1761858344000},"page":"1696-1706","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Systematic Review of the Definition of Cure and of Curative-intent Treatments in Early Bladder Cancer"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0767-3465","authenticated-orcid":false,"given":"F\u00e9lix","family":"Guerrero-Ramos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Schwenke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siobh\u00e1n","family":"Mulhern-Haughey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Pisini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Azough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Rijken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Van Beekhuizen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Freitag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhiannon","family":"Campden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.10.002_b0005","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO guideline","volume":"3","author":"Chang","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.10.002_b0010","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1200\/JCO.2015.65.9797","article-title":"Guideline on muscle-invasive and metastatic bladder cancer (European Association of Urology guideline): American Society of Clinical Oncology clinical practice guideline endorsement","volume":"34","author":"Milowsky","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.10.002_b0015","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2025.10.002_b0020","series-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","author":"Holzbeierlein","year":"2024"},{"key":"10.1016\/j.euo.2025.10.002_b0025","doi-asserted-by":"crossref","first-page":"866","DOI":"10.6004\/jnccn.2022.0041","article-title":"NCCN guidelines\u00ae insights: bladder cancer, version 2.2022","volume":"8","author":"Flaig","year":"2022","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.euo.2025.10.002_b0030","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.3390\/jpm12101745","article-title":"Advanced bladder cancer: changing the treatment landscape","volume":"12","author":"Bilim","year":"2022","journal-title":"J Pers Med"},{"key":"10.1016\/j.euo.2025.10.002_b0035","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.3390\/cancers13194762","article-title":"SOGUG Multidisciplinary Working Group. Recent Advances in the management of patients with non-muscle-invasive bladder cancer using a multidisciplinary approach: practical recommendations from the Spanish Oncology Genitourinary (SOGUG) Working Group","volume":"19","author":"Rubio-Briones","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.euo.2025.10.002_b0040","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1200\/JCO.2011.34.6056","article-title":"Overall survival as the outcome for randomized clinical trials with effective subsequent therapies","volume":"29","author":"Korn","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.10.002_b0045","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/jnci\/djz030","article-title":"Assessing long-term survival benefits of immune checkpoint inhibitors using the net survival benefit","volume":"11","author":"P\u00e9ron","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euo.2025.10.002_b0050","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40273-016-0401-4","article-title":"Use of intermediate endpoints in the economic evaluation of new treatments for advanced cancer and methods adopted when suitable overall survival data are not available","volume":"9","author":"Beauchemin","year":"2016","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.euo.2025.10.002_b0055","unstructured":"National Institute for Health and Care Excellence. Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease. Technology appraisal guidance TA684. London, UK: NICE; 2021."},{"key":"10.1016\/j.euo.2025.10.002_b0060","series-title":"Benefit assessment procedure for the active substance pembrolizumab (new indication: melanoma, adjuvant therapy, \u226512 years, monotherapy)","author":"Bundesausschuss","year":"2023"},{"key":"10.1016\/j.euo.2025.10.002_b0065","unstructured":"National Cancer Institute. Relapse-free survival. https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/relapse-free-survival."},{"key":"10.1016\/j.euo.2025.10.002_b0070","doi-asserted-by":"crossref","first-page":"5861","DOI":"10.1007\/s00432-022-04564-3","article-title":"Will repeat resection after initial transurethral en bloc resection benefit patients with high-risk non-muscle-invasive bladder cancer? A propensity score matching analysis","volume":"149","author":"Zhou","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.euo.2025.10.002_b0075","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1080\/2090598X.2023.2190687","article-title":"Can we offer additional BCG therapy for three-month BCG refractory high grade\/T1, Tis bladder cancer patients?","volume":"21","author":"Elsawy","year":"2023","journal-title":"Arab J Urol"},{"key":"10.1016\/j.euo.2025.10.002_b0080","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/jjco\/hyab210","article-title":"Potential therapeutic effects of adjuvant chemotherapy after neoadjuvant chemotherapy for locally advanced muscle-invasive bladder cancer","volume":"52","author":"Omura","year":"2022","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.euo.2025.10.002_b0085","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/7306198","article-title":"Comparing long-term survival outcomes for muscle-invasive bladder cancer patients who underwent with radical cystectomy and bladder-sparing trimodality therapy: a multicentre cohort analysis","volume":"2022","author":"Qiu","year":"2022","journal-title":"J Oncol"},{"key":"10.1016\/j.euo.2025.10.002_b0090","doi-asserted-by":"crossref","first-page":"107.e9","DOI":"10.1016\/j.urolonc.2022.09.013","article-title":"Recurrence patterns in bladder cancer patients with no residual disease (pT0N0) at radical cystectomy: a 20-year experience","volume":"41","author":"Douglawi","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2025.10.002_b0095","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.euf.2023.06.012","article-title":"Long-term recurrence rates of low-risk non-muscle-invasive bladder cancer-how long is cystoscopic surveillance necessary?","volume":"10","author":"Ma","year":"2024","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2025.10.002_b0100","doi-asserted-by":"crossref","first-page":"851.e11","DOI":"10.1016\/j.urolonc.2020.07.014","article-title":"Association of bacillus Calmette-Guerin shortages with bladder cancer recurrence: a single-center retrospective study","volume":"38","author":"Lee","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2025.10.002_b0105","doi-asserted-by":"crossref","first-page":"e1003","DOI":"10.1016\/j.clgc.2019.05.028","article-title":"Efficacy of immediate postoperative instillation of chemotherapy for primary non-muscle-invasive bladder cancer in real-world clinical practice","volume":"17","author":"Murakami","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2025.10.002_b0110","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.euf.2019.04.021","article-title":"Androgen suppression therapy is associated with lower recurrence of non-muscle-invasive bladder cancer","volume":"7","author":"Wu","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2025.10.002_b0115","doi-asserted-by":"crossref","first-page":"711.e1","DOI":"10.1016\/j.clgc.2023.04.011","article-title":"The impact of blue light cystoscopy use among nonmuscle invasive bladder cancer patients in an equal access setting: implications on recurrence and time to recurrence","volume":"21","author":"Das","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2025.10.002_b0120","doi-asserted-by":"crossref","first-page":"8945","DOI":"10.1007\/s00432-023-04739-6","article-title":"The application of gemcitabine and pirarubicin in patients with non-muscle invasive bladder cancer","volume":"149","author":"Wang","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.euo.2025.10.002_b0125","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3233\/BLC-190262","article-title":"Does 5-alpha reductase inhibitor use improve the efficacy of intravesical bacille Calmette-Gu\u00e9rin (BCG) for non-muscle invasive bladder cancer?","volume":"6","author":"Al-Hogbani","year":"2020","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.euo.2025.10.002_b0130","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/bju.15209","article-title":"Recurrence- and progression-free survival in intermediate-risk non-muscle-invasive bladder cancer: the impact of conditional evaluation and subclassification","volume":"127","author":"Kohada","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2025.10.002_b0135","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2340\/sju.v59.24024","article-title":"DaBlaCa-17: nationwide observational study in Denmark on survival before and after implementation of neoadjuvant chemotherapy prior to cystectomy for muscle-invasive bladder cancer","volume":"59","author":"Korner","year":"2024","journal-title":"Scand J Urol"},{"key":"10.1016\/j.euo.2025.10.002_b0140","doi-asserted-by":"crossref","first-page":"e6972","DOI":"10.1002\/cam4.6972","article-title":"Comparative survival analysis of bladder preservation therapy versus radical cystectomy in muscle-invasive bladder cancer","volume":"13","author":"Kang","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.euo.2025.10.002_b0145","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/bju.15289","article-title":"Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis","volume":"128","author":"Soria","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2025.10.002_b0150","article-title":"Three vs. four cycles of neoadjuvant chemotherapy for localized muscle invasive bladder cancer undergoing radical cystectomy: a retrospective multi-institutional analysis. Front","volume":"11","author":"Ferro","year":"2021","journal-title":"Oncol"},{"key":"10.1016\/j.euo.2025.10.002_b0155","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s11255-019-02087-4","article-title":"Long term oncologic outcome in patients with bladder cancer after radical cystectomy: impact of carcinoma in situ in the era of neoadjuvant chemotherapy","volume":"51","author":"Amini","year":"2019","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.euo.2025.10.002_b0160","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1016\/j.clgc.2020.11.002","article-title":"Second-line conservative device-assisted intravesical treatment in selected patients with recurrent high-risk non-muscle-invasive bladder cancer","volume":"19","author":"Di Gianfrancesco","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2025.10.002_b0165","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3390\/medicina59010050","article-title":"Long-term outcome of patients with stage II and III muscle-invasive urothelial bladder cancer after multimodality approach. Which is the best option?","volume":"59","author":"Trifanescu","year":"2022","journal-title":"Medicina"},{"key":"10.1016\/j.euo.2025.10.002_b0170","doi-asserted-by":"crossref","first-page":"457.e17","DOI":"10.1016\/j.urolonc.2023.09.017","article-title":"Effectiveness of perioperative chemotherapy and radical cystectomy in treating bladder cancer","volume":"41","author":"Li","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2025.10.002_b0175","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3233\/BLC-211556","article-title":"Implications for efficacy and safety of total dose and dose-intensity of neoadjuvant gemcitabine-cisplatin in muscle-invasive bladder cancer: three-week versus four-week regimen","volume":"8","author":"Holmsten","year":"2022","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.euo.2025.10.002_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109584","article-title":"Chemoradiation for muscle-invasive bladder cancer using 5-fluorouracil versus capecitabine: a nationwide cohort study","volume":"183","author":"de Haar-Holleman","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.euo.2025.10.002_b0185","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.clgc.2019.11.005","article-title":"Clinical outcomes of patients with histologic variants of urothelial carcinoma treated with selective tetramodal bladder-preservation therapy incorporating consolidative partial cystectomy","volume":"18","author":"Kijima","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2025.10.002_b0190","series-title":"EAU Guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS): limited text update April 2024","author":"Gontero","year":"2024"},{"key":"10.1016\/j.euo.2025.10.002_b0195","first-page":"E424","article-title":"Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer \u2013 full-text","volume":"15","author":"Bhindi","year":"2021","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.euo.2025.10.002_b0200","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.10.002_b0205","unstructured":"National Institute for Health and Care Excellence. Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer. Technology appraisal guidance TA746. London, UK: NICE; 2021. https:\/\/www.nice.org.uk\/guidance\/ta746."},{"key":"10.1016\/j.euo.2025.10.002_b0210","unstructured":"National Institute for Health and Care Excellence. Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer. Technology appraisal guidance TA823. London, UK: NICE; 2022. https:\/\/www.nice.org.uk\/guidance\/ta823."},{"key":"10.1016\/j.euo.2025.10.002_b0215","unstructured":"National Institute for Health and Care Excellence. Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma. Technology appraisal guidance TA544. London, UK: NICE; 2018. https:\/\/www.nice.org.uk\/guidance\/ta544."},{"key":"10.1016\/j.euo.2025.10.002_b0220","doi-asserted-by":"crossref","first-page":"6765","DOI":"10.2147\/CMAR.S213553","article-title":"Ultra-late recurrence of non-small cell lung cancer over 10 years after curative resection","volume":"11","author":"Sonoda","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.euo.2025.10.002_b0225","doi-asserted-by":"crossref","first-page":"721","DOI":"10.21037\/atm-21-1458","article-title":"Exploring the concepts and practices of advanced breast cancer treatment: a narrative review","volume":"8","author":"Wang","year":"2021","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.euo.2025.10.002_b0230","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3233\/BLC-230047","article-title":"Comparative analysis of very reduced vs full dose BCG treatment for high-risk non-muscle invasive bladder cancer: a contemporary experience from Chile","volume":"9","author":"Grajales","year":"2023","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.euo.2025.10.002_b0235","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.10.002_b0240","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.10.002_b0245","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.euo.2024.01.017","article-title":"Unlocking the potential of adequate bacillus Calmette-Gu\u00e9rin immunotherapy in very-high-risk non\u2013muscle-invasive bladder carcinoma: a multicenter analysis of oncological outcomes and risk dynamics","volume":"7","author":"Subiela","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.10.002_b0250","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00345-016-1856-9","article-title":"Is it possible to stop follow-up of patients with primary T1G3 urothelial carcinoma of the bladder managed with intravesical bacille Calmette-Gu\u00e9rin immunotherapy?","volume":"35","author":"Golabek","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2025.10.002_b0255","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/JU.0000000000000001","article-title":"Guidelines for reporting of statistics for clinical research in urology","volume":"201","author":"Assel","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.10.002_b0260","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ijrobp.2023.07.027","article-title":"Disease-free survival of patients with muscle-invasive bladder cancer treated with radical cystectomy versus bladder-preserving therapy: a nationwide study","volume":"118","author":"Bruck","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euo.2025.10.002_b0265","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/CU9.0000000000000009","article-title":"Bladder preservation versus radical cystectomy in transitional cell carcinoma and squamous cell carcinoma muscle invasive bladder cancer","volume":"15","author":"Mohamed","year":"2021","journal-title":"Curr Urol"},{"key":"10.1016\/j.euo.2025.10.002_b0270","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/bju.15434","article-title":"Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration","volume":"128","author":"Ravi","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2025.10.002_b0275","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1080\/2090598X.2021.1874628","article-title":"Assessment of the oncological outcomes of three different bacillus Calmette-Gu\u00e9rin strains in patients with high-grade T1 non-muscle-invasive bladder cancer","volume":"19","author":"Nowak","year":"2021","journal-title":"Arab J Urol"},{"key":"10.1016\/j.euo.2025.10.002_b0280","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000527718","article-title":"Efficacy of intravesical instillation therapy with low-dose Tokyo-172 bacillus Calmette-Guerin to prevent recurrence of non-muscle-invasive bladder cancer and treat carcinoma in situ: a multi-institutional retrospective study","volume":"107","author":"Tachibana","year":"2023","journal-title":"Urol Int"},{"key":"10.1016\/j.euo.2025.10.002_b0285","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.euo.2021.04.003","article-title":"Implications of guideline-based, risk-stratified restaging transurethral resection of high-grade Ta urothelial carcinoma on bacillus Calmette-Guerin therapy outcomes","volume":"5","author":"Hensley","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.10.002_b0290","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.euf.2023.04.012","article-title":"Comparison of bacillus Calmette-Guerin maintenance therapy with monthly instillations and the Southwest Oncology Group protocol in the treatment of non-muscle-invasive bladder cancer","volume":"9","author":"Nurminen","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2025.10.002_b0295","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1007\/s00432-021-03571-0","article-title":"Efficacy of three BCG strains (Connaught, TICE and RIVM) with or without secondary resection (re-TUR) for intermediate\/high-risk non-muscle-invasive bladder cancers: results from a retrospective single-institution cohort analysis","volume":"147","author":"Del Giudice","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.euo.2025.10.002_b0300","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3390\/cancers14040887","article-title":"Compared efficacy of adjuvant intravesical BCG-TICE vs. BCG-RIVM for high-risk non-muscle invasive bladder cancer (NMIBC): a propensity score matched analysis","volume":"14","author":"Del Giudice","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.euo.2025.10.002_b0305","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.21037\/tau.2020.03.40","article-title":"Clinical outcomes and survival differences between primary, secondary and concomitants carcinoma in situ of urinary bladder treated with BCG immunotherapy","volume":"9","author":"Piszczek","year":"2020","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.euo.2025.10.002_b0310","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s12885-021-07966-7","article-title":"Non-maintenance intravesical bacillus Calmette-Gu\u00e9rin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study","volume":"21","author":"Miyake","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.euo.2025.10.002_b0315","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1111\/iju.15294","article-title":"Improving compliance with guidelines may lead to favorable clinical outcomes for patients with non-muscle-invasive bladder cancer: Aretrospective multicenter study","volume":"30","author":"Sato","year":"2023","journal-title":"Int J Urol"},{"key":"10.1016\/j.euo.2025.10.002_b0320","doi-asserted-by":"crossref","first-page":"5105","DOI":"10.3390\/jcm10215105","article-title":"Long-term experience with hyperthermic chemotherapy (HIVEC) using mitomycin-C in patients with non-muscle invasive bladder cancer in Spain","volume":"10","author":"Plata","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.euo.2025.10.002_b0325","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3390\/cancers13030377","article-title":"Long-term experience with radiofrequency-induced hyperthermia combined with intravesical chemotherapy for non-muscle invasive bladder cancer","volume":"13","author":"Brummelhuis","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.euo.2025.10.002_b0330","first-page":"284","article-title":"Does restaging transurethral resection of bladder tumour influence outcomes in patients treated with BCG immunotherapy? 491 cases in 20 years\u2019 experience","volume":"14","author":"Krajewski","year":"2019","journal-title":"Wideochir Inne Tech Maloinwazyjne"},{"key":"10.1016\/j.euo.2025.10.002_b0335","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/bju.16371","article-title":"Adjuvant intravesical therapy in intermediate-risk non-muscle-invasive bladder cancer","volume":"134","author":"Laukhtina","year":"2024","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2025.10.002_b0340","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.570077","article-title":"Association between antibiotic treatment and the efficacy of intravesical BCG therapy in patients with high-risk non-muscle invasive bladder cancer","volume":"11","author":"Pak","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.euo.2025.10.002_b0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.pdpdt.2023.103294","article-title":"Risks and benefits of transurethral resection of the bladder tumor using photodynamic diagnosis with oral 5-aminolevulinic acid hydrochloride according to age and history of recurrence in patients with non-muscle invasive bladder cancer","volume":"41","author":"Kobayashi","year":"2023","journal-title":"Photodiagn Photodyn Ther"},{"key":"10.1016\/j.euo.2025.10.002_b0350","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12894-020-00599-1","article-title":"Can a second resection be avoided after initial thulium laser endoscopic en bloc resection for non-muscle invasive bladder cancer? A retrospective single-center study of 251 patients","volume":"20","author":"Zhou","year":"2020","journal-title":"BMC Urol"},{"key":"10.1016\/j.euo.2025.10.002_b0355","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1177\/2051415820981207","article-title":"Long-term follow-up of holmium-YAG laser vaporisation of bladder urothelial carcinoma","volume":"15","author":"Bazo","year":"2022","journal-title":"J Clin Urol"},{"key":"10.1016\/j.euo.2025.10.002_b0360","article-title":"Overnight continuous saline bladder irrigation after en bloc resection of bladder tumor does not improve oncological outcomes in patients who have received intravesical chemotherapy","volume":"11","author":"Yang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.euo.2025.10.002_b0365","doi-asserted-by":"crossref","first-page":"60.e1","DOI":"10.1016\/j.urolonc.2021.06.018","article-title":"Intermediate-term survival of robot-assisted versus open radical cystectomy for muscle-invasive and high-risk non-muscle invasive bladder cancer in The Netherlands","volume":"40","author":"Hinsenveld","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2025.10.002_b0370","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.eururo.2019.06.032","article-title":"Incremental utility of adjuvant chemotherapy in muscle-invasive bladder cancer: quantifying the relapse risk associated with therapeutic effect","volume":"76","author":"Pederzoli","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.10.002_b0375","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/iju.14749","article-title":"Impact of neoadjuvant chemotherapy on survival and recurrence patterns after robot-assisted radical cystectomy for muscle-invasive bladder cancer: results from the International Robotic Cystectomy Consortium","volume":"29","author":"Gopalakrishnan","year":"2022","journal-title":"Int J Urol"},{"key":"10.1016\/j.euo.2025.10.002_b0380","doi-asserted-by":"crossref","first-page":"404","DOI":"10.5489\/cuaj.6459","article-title":"Canadian experience of neoadjuvant chemotherapy on bladder recurrences in patients managed with trimodal therapy for muscle-invasive bladder cancer","volume":"14","author":"Ajib","year":"2020","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.euo.2025.10.002_b0385","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.clgc.2023.10.013","article-title":"Neoadjuvant chemoradiotherapy followed by radical cystectomy for muscle-invasive bladder cancer: analysis of efficacy and safety in 119 patients","volume":"22","author":"Fujiwara","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2025.10.002_b0390","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00345-019-02842-3","article-title":"Long-term oncologic outcomes of robot-assisted radical cystectomy (RARC) with totally intracorporeal urinary diversion (ICUD): a multi-center study","volume":"38","author":"Brassetti","year":"2020","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2025.10.002_b0395","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/bju.14736","article-title":"Selective tetramodal bladder-preservation therapy, incorporating induction chemoradiotherapy and consolidative partial cystectomy with pelvic lymph node dissection for muscle-invasive bladder cancer: oncological and functional outcomes of 107 patients","volume":"124","author":"Kijima","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2025.10.002_b0400","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.clgc.2019.09.005","article-title":"Effectiveness of intravesical doxorubicin immediately following resection of primary non\u2013muscle-invasive bladder cancer: a propensity score-matched analysis","volume":"18","author":"Fukuokaya","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2025.10.002_b0405","doi-asserted-by":"crossref","DOI":"10.1590\/1806-9282.20231116","article-title":"Increased risk of bladder cancer recurrence due to bacillus Calmette-Gu\u00e9rin shortage in Brazil","volume":"70","author":"Murta","year":"2024","journal-title":"Rev Assoc Med Bras"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125002561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125002561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T08:40:39Z","timestamp":1778143239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125002561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":81,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2588931125002561"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.10.002","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic Review of the Definition of Cure and of Curative-intent Treatments in Early Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}